<code id='2F3BCABAFD'></code><style id='2F3BCABAFD'></style>
    • <acronym id='2F3BCABAFD'></acronym>
      <center id='2F3BCABAFD'><center id='2F3BCABAFD'><tfoot id='2F3BCABAFD'></tfoot></center><abbr id='2F3BCABAFD'><dir id='2F3BCABAFD'><tfoot id='2F3BCABAFD'></tfoot><noframes id='2F3BCABAFD'>

    • <optgroup id='2F3BCABAFD'><strike id='2F3BCABAFD'><sup id='2F3BCABAFD'></sup></strike><code id='2F3BCABAFD'></code></optgroup>
        1. <b id='2F3BCABAFD'><label id='2F3BCABAFD'><select id='2F3BCABAFD'><dt id='2F3BCABAFD'><span id='2F3BCABAFD'></span></dt></select></label></b><u id='2F3BCABAFD'></u>
          <i id='2F3BCABAFD'><strike id='2F3BCABAFD'><tt id='2F3BCABAFD'><pre id='2F3BCABAFD'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:992
          Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT
          Adobe

          For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

          But just because it was simple didn’t mean it was going to work.

          advertisement

          The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

          read more
          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more

          Pushing for an NIH office for post

          MarkWilson/NewsmakersWhentheWhiteHousereleasedPresidentBiden’s2025budgetrequeststhisweek,fundingforb